Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
144,690,313
-
Share change
-
+28,745,652
-
Total reported value
-
$133,837,483
-
Put/Call ratio
-
40%
-
Price per share
-
$0.92
-
Number of holders
-
85
-
Value change
-
+$26,555,200
-
Number of buys
-
56
-
Number of sells
-
20
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q2 2023
As of 30 Jun 2023,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
85 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
144,690,313 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, BAILLIE GIFFORD & CO, NEA Management Company, LLC, BAKER BROS. ADVISORS LP, PFM Health Sciences, LP, Long Focus Capital Management, LLC, MPM ASSET MANAGEMENT LLC, BIOIMPACT CAPITAL LLC, TANG CAPITAL MANAGEMENT LLC, and BANK OF AMERICA CORP /DE/.
This page lists
85
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.